MedPath

Mechanical Device for the Relief of Hot Flashes

Phase 2
Completed
Conditions
Hot Flashes
Interventions
Device: Inactive device
Device: Menopod
Registration Number
NCT01281332
Lead Sponsor
Queen's University
Brief Summary

Hypothesis: A mechanical device when applied to the back of the neck at the onset of a menopausal hot flash will attenuate the severity and duration of symptoms providing women with a reassuring non-hormonal intervention to improve quality of life in the menopausal transition. This pilot study will evaluate the effectiveness of this unit.

The mechanism of action of the device will not be revealed in advance.

Detailed Description

This is a pilot study to test logistics and gather information for planning the definite trial. We will randomly allocate 40 subjects to receive either the active Menopod device (n=20) or a sham device with the mechanism disabled (n=20).

We will recruit menopausal women with moderate to severe hot flashes (as defined by FDA standards this means a minimum of 7 per day).

The two primary outcome parameters are the hot flash score which is the product of frequency x intensity (Sloan 2001), and the average duration (in minutes) of hot flash episodes over the course of one day. These outcomes will be self-recorded by subjects in a diary designed by our research team on five separate days throughout the course of the study, once during the evaluation phase and once per week over the four week treatment phase. The two summary measures will be the changes from baseline to the last record collected for hot flash scores and average durations. Delta values (assessment phase minus fourth treatment period) will be compared between the two treatment groups (active versus sham device) using t tests (IBM SPSS Statistics version 21).

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
40
Inclusion Criteria
  • Age range: 40 to 65 years
  • Healthy postmenopausal woman
  • natural or surgical menopause
  • FSH > 30 IU/L
  • Amenorrhea > 6 months prior to study
  • Minimum of 7 moderate hot flashes per day documented in diary during evaluation phase
Exclusion Criteria
  • Any therapy for hot flashes prior to or during study
  • Obesity: BMI > 35
  • Alcohol abuse
  • Drug abuse
  • Unable to use device as per protocol
  • Unable to complete required documentation
  • Serious medical condition:
  • coronary heart disease
  • stroke
  • chronic renal or hepatic disease
  • diabetes
  • depression or other psychiatric illness
  • cancer

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Sham deviceInactive deviceInactive device.
Menopod deviceMenopodMenopod®
Primary Outcome Measures
NameTimeMethod
Hot flash score and durationChange from baseline to end of study (week 4).

Hot flash score is a product of frequency x intensity (Sloan 2001). Duration (minutes) will be recorded in diary.

Secondary Outcome Measures
NameTimeMethod
Quality of Life (QOL) and AnxietyChange from baseline to end of study (week 4).

Subjects will complete the Hot Flash Related Daily Interference Scale once during the evaluation phase and once per week over the four week treatment phase (Carpenter 2001). This validated questionnaire assesses the impact of hot flashes on daily activities and overall QOL. They will also complete the Zung Self-Rating Anxiety Scale (Zung 1971). This validated 20-item questionnaire measures anxiety with established normal, mild to moderate, marked to severe and extreme levels.

Carpenter JS. The Hot Flash Related Daily Interference Scale: a tool for assessing the impact of hot flashes on quality of life following breast cancer. J Pain Symptom Manage 2001 Dec;22(6):979-89.

Zung WW. A rating instrument for anxiety disorders. Psychosomatics 1971 Nov-Dec;12(6):371-9.

Trial Locations

Locations (1)

Kingston General Hospital

🇨🇦

Kingston, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath